Transfection Technologies Market Size is around USD 1023.8 million in 2022 and is poised to grow at a significant CAGR of 8.9% over 2022–2028. Transfection is the process of introducing nucleic acids into eukaryotic cells by chemical or physical methods. It helps in the study of gene function and protein expression in a cellular environment. The main purpose of transfection is to study the function of genes or gene products, by enhancing or inhibiting specific gene expression in cells, and to produce recombinant proteins in mammalian cells. There are various transfection methods are there like lipofection, electroporation, nucleofection, co-transfection, cationic lipid transfection, and in-vivo transfection. Advances in cell research technologies and therapeutic deliveries, and a rise in funding for research and development in transfection technology by government and private firms are boosting the global transfection technologies market growth. Also, the prevalence of cancer, obesity, and various chronic lifestyle diseases is rising the demand for transfection technology due to research in cell-based therapies. Reagent-based transfection technology is expected to grow at a higher pace and will dominate the market due to its cost-effectiveness and less complicated methods. However, instrument-based methods, such as biolistic technology, and microinjection are also driving the global transfection market growth. The key global players like Bio-RAD Laboratories, Lonza Group AG, Maxcyte, Mirus Bio, Polyplus Transfection, Promega Corporation, and Thermo Fisher Scientific are influencing the infection technologies market growth through new innovation and investment in the research and development sector. The transfection technologies market is segmented into North America, Europe, Latin America, Asia Specific, and the Middle East and Africa. North America holds the major transfection technologies market share due to an increase in the cases of infectious diseases.
Recent Market Developments:
In Aug 2022, Synthego launched engineered cell libraries to validate targets with speed and accelerate drug discovery.
In Aug 2021, Polyplus launched a new transfection reagent for large-scale viral vector production.